Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Hypofractionated, Dose Escalation Radiotherapy and Brachytherapy for Intermediate-risk Adenocarcinoma of the Prostate with 6 Versus 12 Months of Hormonal Manipulation

NCT06855589 is registered in ClinicalTrials.gov with Charles LeMoyne Hospital as lead sponsor.

NCT NCT06855589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06855589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy and Brachytherapy for Intermediate-risk Adenocarcinoma of the Prostate with 6 Versus 12 Months of Hormonal Manipulation
Lead sponsor
Charles LeMoyne Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
March 31, 2025
Completion date
March 31, 2034
Enrollment
400 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer (adenocarcinoma)